Loading...
•
Dec 31, 2022
Ginkgo Bioworks Q4 2022 Earnings Report
Ginkgo Bioworks reported a decrease in total revenue but an increase in foundry revenue for the fourth quarter of 2022.
Key Takeaways
Ginkgo Bioworks reported a decrease in total revenue for Q4 2022, primarily due to an expected reduction in K-12 COVID-19 testing services. However, Foundry revenue increased, and the company added 20 new Cell Programs. The company's cash balance remains strong, providing flexibility for future growth.
Total revenue for Q4 2022 was $98 million, down 34% year-over-year.
Foundry revenue for Q4 2022 was $53 million, up 56% year-over-year.
Biosecurity revenue for Q4 2022 was $45 million, down 61% year-over-year.
Loss from operations for Q4 2022 was $(235) million, compared to $(1,685) million in the prior year period.
Ginkgo Bioworks
Ginkgo Bioworks
Ginkgo Bioworks Revenue by Segment
Revenue by Segment
Cell Engineering Revenue
CapyFin.comBiosecurity Revenue
CapyFin.com Forward Guidance
Ginkgo expects to add 100 new Cell Programs to the Foundry platform and anticipates total revenue of at least $275 million in 2023, with Foundry revenue of at least $175 million and Biosecurity revenue of at least $100 million.
Positive Outlook
- Expects to add 100 new Cell Programs to the Foundry platform in 2023.
- Anticipates total revenue of at least $275 million in 2023.
- Forecasts Foundry revenue of at least $175 million in 2023.
- Projects Biosecurity revenue of at least $100 million in 2023.
- Expects nearly half of Biosecurity revenue to come from emerging product lines.
Revenue & Expenses
Visualization of income flow from segment revenue to net income